ArticleThe journal of headache and pain2025
Short-term prevention of perimenstrual migraine with rimegepant.
Article in The journal of headache and pain, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Sex-specific considerations in migraine therapy.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMenstrually-related migraine (MRM) affects approximately 31–52% of women with migraine and are characterized by increased frequency, severity, and reduced response to conventional therapy during the perimenstrual window. Traditional short-term prevention with non-steroidal anti-inflammatory drugs (NSAIDs) or triptans often fails due to intolerance or contraindications. Rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist with indication for both acute and preventive therapy, may offer a novel short-term prophylactic option for perimenstrual migraine.
methodsThis hypothesis-generating case series includes five women, aged 22–42 years, with episodic migraine and regular menstrual cycles, who received rimegepant 75 mg orally disintegrating tablet every other day, initiated two days prior menstruation and continued until two days post-menstruation. Patients recorded daily headache diaries, and key outcomes included reduction of perimenstrual migraine days, overall migraine frequency, tolerability, and adverse events. Follow-up was conducted after 3–4 cycles.
resultsRimegepant prevented perimenstrual attacks in 17/20 cycles (85%) with no treatment-related adverse events in this small cohort. However, sustained monthly migraine day reduction occurred in only one patient (20%). Three patients (60%) experienced delayed migraine onset 3–7 days post-menstruation, suggesting “temporal displacement” rather than complete prevention. All patients reported high satisfaction with perimenstrual symptom control.
conclusionsShort-term rimegepant was well tolerated and prevented anticipated perimenstrual migraine attacks in most cases. The observed temporal displacement of migraine supports complex hormonal and CGRP-independent mechanisms in menstrual migraine. Randomized controlled trials are warranted to optimize treatment protocols and confirm these preliminary findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.